Modification of feeding behaviour

• US 7,825,091 B2
• Filed: 07/23/2007
• Issued: 11/02/2010
• Est. Priority Date: 01/10/2003
• Status: Expired due to Fees

• Current Assignee: Imperial Innovations Limited (Imperial College London)
• Original Assignee: Imperial Innovations Limited (Imperial College London)
• Inventors: Small, Caroline Jane, Ghatei, Mohammad Ali, Bloom, Stephen Robert, Dakin, Catherine Louise
• Primary Examiner(s): Kosar; Andrew D
• Application Number:
  US11/781,773
• Publication Number:
  US 20080064636A1
• Time in Patent Office: 1,198 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/2271 Neuropeptide Y
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics

Abstract

The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and/or increase energy expenditure.

Claims

1. A method for the prevention or treatment of excess weight in a subject mammal, which comprises administering oxyntomodulin and PYY to the subject.

2. The method according to claim 1, which is a method for the reduction or prevention of obesity.

3. The method according to claim 1, which comprises administering PYY_3-36.

4. The method according to claim 1, wherein the oxyntomodulin is administered via a route peripheral to the brain.

5. The method according to claim 1, wherein the PYY is administered via a route peripheral to the brain.

6. The method according to claim 4, wherein the oxyntomodulin is administered by a route selected from the group consisting of oral, rectal, intravenous, intramuscular, intraperitoneal, buccal, sublingual, nasal, subcutaneous, and transdermal administration.

7. The method according to claim 5, wherein the PYY is administered by a route selected from the group consisting of oral, rectal, intravenous, intramuscular, intraperitoneal, buccal sublingual, nasal, subcutaneous, and transdermal administration.

8. The method according to claim 1, wherein the oxyntomodulin is administered peripherally at a dose of 0.1 nmoles or more per kg body weight of the subject.

9. The method according to claim 1, wherein the oxyntomodulin is administered peripherally at a dose of up to 12 nmoles per kg body weight.

10. The method according to claim 1, wherein the oxyntomodulin is administered at a dose of 0.5 mg to 2 mg before meals.

11. The method according to claim 1, wherein the PYY is administered peripherally at a dose of 0.1 nmoles per kg body weight of the subject or more.

12. The method according to claim 1, wherein the PYY is administered peripherally at a dose of up to 3.2 nmoles per kg body weight.

13. The method according to claim 1, wherein the oxyntomodulin and the PYY are administered simultaneously, or sequentially in any order.